709 related articles for article (PubMed ID: 23325084)
1. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease.
Ruiz S; Pergola PE; Zager RA; Vaziri ND
Kidney Int; 2013 Jun; 83(6):1029-41. PubMed ID: 23325084
[TBL] [Abstract][Full Text] [Related]
2. Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases.
Saito H
Biochem Pharmacol; 2013 Apr; 85(7):865-72. PubMed ID: 23333765
[TBL] [Abstract][Full Text] [Related]
3. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KEAP1-NRF2 System to Prevent Kidney Disease Progression.
Nezu M; Suzuki N; Yamamoto M
Am J Nephrol; 2017; 45(6):473-483. PubMed ID: 28502971
[TBL] [Abstract][Full Text] [Related]
5. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Khazaeli M; Yuan J; Meyer CJ
Xenobiotica; 2014 Jun; 44(6):570-8. PubMed ID: 24195589
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
[TBL] [Abstract][Full Text] [Related]
7. Targeting Nrf2 in Protection Against Renal Disease.
Guerrero-Hue M; Farre-Alins V; Palomino-Antolin A; Parada E; Rubio-Navarro A; Egido J; Egea J; Moreno JA
Curr Med Chem; 2017; 24(33):3583-3605. PubMed ID: 28494744
[TBL] [Abstract][Full Text] [Related]
8. Effect of redox modulating NRF2 activators on chronic kidney disease.
Choi BH; Kang KS; Kwak MK
Molecules; 2014 Aug; 19(8):12727-59. PubMed ID: 25140450
[TBL] [Abstract][Full Text] [Related]
9. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.
Kim HJ; Vaziri ND
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F662-71. PubMed ID: 20007347
[TBL] [Abstract][Full Text] [Related]
10. Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2.
Pedruzzi LM; Cardozo LF; Daleprane JB; Stockler-Pinto MB; Monteiro EB; Leite M; Vaziri ND; Mafra D
J Nephrol; 2015 Aug; 28(4):495-501. PubMed ID: 25585822
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats.
Javkhedkar AA; Quiroz Y; Rodriguez-Iturbe B; Vaziri ND; Lokhandwala MF; Banday AA
Am J Physiol Regul Integr Comp Physiol; 2015 May; 308(10):R840-6. PubMed ID: 25761698
[TBL] [Abstract][Full Text] [Related]
12. GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition.
Lu M; Wang P; Qiao Y; Jiang C; Ge Y; Flickinger B; Malhotra DK; Dworkin LD; Liu Z; Gong R
Redox Biol; 2019 Sep; 26():101275. PubMed ID: 31349118
[TBL] [Abstract][Full Text] [Related]
13. Bardoxolone treatment alleviates lipopolysaccharide (LPS)-induced acute lung injury through suppressing inflammation and oxidative stress regulated by Nrf2 signaling.
Pei X; Zhang XJ; Chen HM
Biochem Biophys Res Commun; 2019 Aug; 516(1):270-277. PubMed ID: 31248593
[TBL] [Abstract][Full Text] [Related]
14. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
de Zeeuw D; Akizawa T; Agarwal R; Audhya P; Bakris GL; Chin M; Krauth M; Lambers Heerspink HJ; Meyer CJ; McMurray JJ; Parving HH; Pergola PE; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Warnock DG; Wittes J; Chertow GM
Am J Nephrol; 2013; 37(3):212-22. PubMed ID: 23467003
[TBL] [Abstract][Full Text] [Related]
15. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy.
Aminzadeh MA; Nicholas SB; Norris KC; Vaziri ND
Nephrol Dial Transplant; 2013 Aug; 28(8):2038-45. PubMed ID: 23512109
[TBL] [Abstract][Full Text] [Related]
16. Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.
Lau WL; Liu SM; Pahlevan S; Yuan J; Khazaeli M; Ni Z; Chan JY; Vaziri ND
Dig Dis Sci; 2015 May; 60(5):1215-22. PubMed ID: 25399330
[TBL] [Abstract][Full Text] [Related]
17. Deal watch: Abbott boosts investment in NRF2 activators for reducing oxidative stress.
Crunkhorn S
Nat Rev Drug Discov; 2012 Feb; 11(2):96. PubMed ID: 22293557
[No Abstract] [Full Text] [Related]
18. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
[TBL] [Abstract][Full Text] [Related]
19. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
Wu J; Liu X; Fan J; Chen W; Wang J; Zeng Y; Feng X; Yu X; Yang X
Toxicology; 2014 Apr; 318():22-31. PubMed ID: 24530882
[TBL] [Abstract][Full Text] [Related]
20. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Impellizzeri D; Esposito E; Attley J; Cuzzocrea S
Pharmacol Res; 2014 Mar; 81():91-102. PubMed ID: 24602801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
